Updates in the management of connective tissue disease-associated interstitial lung disease
The occurrence of interstitial lung disease (ILD) in a setting of a well-defined autoimmune disease or in the presence of autoantibodies is being increasingly recognized. The traditional approach to the treatment of connective tissue disease-associated ILD (CTD-ILD) was a combination of glucocortico...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2021-01-01
|
| Series: | Indian Journal of Rheumatology |
| Subjects: | |
| Online Access: | http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2021;volume=16;issue=5;spage=109;epage=115;aulast=Kavadichanda |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832543417030148096 |
|---|---|
| author | Chengappa Kavadichanda G S R S N K Naidu |
| author_facet | Chengappa Kavadichanda G S R S N K Naidu |
| author_sort | Chengappa Kavadichanda |
| collection | DOAJ |
| description | The occurrence of interstitial lung disease (ILD) in a setting of a well-defined autoimmune disease or in the presence of autoantibodies is being increasingly recognized. The traditional approach to the treatment of connective tissue disease-associated ILD (CTD-ILD) was a combination of glucocorticoids and cyclophosphamide or mycophenolate mofetil. Most of the evidence in treating these cases is limited to a few trials in scleroderma and idiopathic pulmonary fibrosis along with several observational studies in other CTDs. Insights into the pathology of these diseases and the associated lung involvement have resulted in the emergence of several immunosuppressive, antifibrotic, and small molecules as alternatives in CTD-ILD. In this review, we have attempted to summarize several emerging therapeutic options for CTD-ILD. |
| format | Article |
| id | doaj-art-46dd3960a66248dbbd97e749c8ea96f4 |
| institution | Kabale University |
| issn | 0973-3698 0973-3701 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Indian Journal of Rheumatology |
| spelling | doaj-art-46dd3960a66248dbbd97e749c8ea96f42025-02-03T11:42:10ZengSAGE PublishingIndian Journal of Rheumatology0973-36980973-37012021-01-0116510911510.4103/0973-3698.332985Updates in the management of connective tissue disease-associated interstitial lung diseaseChengappa KavadichandaG S R S N K NaiduThe occurrence of interstitial lung disease (ILD) in a setting of a well-defined autoimmune disease or in the presence of autoantibodies is being increasingly recognized. The traditional approach to the treatment of connective tissue disease-associated ILD (CTD-ILD) was a combination of glucocorticoids and cyclophosphamide or mycophenolate mofetil. Most of the evidence in treating these cases is limited to a few trials in scleroderma and idiopathic pulmonary fibrosis along with several observational studies in other CTDs. Insights into the pathology of these diseases and the associated lung involvement have resulted in the emergence of several immunosuppressive, antifibrotic, and small molecules as alternatives in CTD-ILD. In this review, we have attempted to summarize several emerging therapeutic options for CTD-ILD.http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2021;volume=16;issue=5;spage=109;epage=115;aulast=Kavadichandaantifibroticbiologicalsconnective tissue disease–interstitial lung diseasetreatment |
| spellingShingle | Chengappa Kavadichanda G S R S N K Naidu Updates in the management of connective tissue disease-associated interstitial lung disease Indian Journal of Rheumatology antifibrotic biologicals connective tissue disease–interstitial lung disease treatment |
| title | Updates in the management of connective tissue disease-associated interstitial lung disease |
| title_full | Updates in the management of connective tissue disease-associated interstitial lung disease |
| title_fullStr | Updates in the management of connective tissue disease-associated interstitial lung disease |
| title_full_unstemmed | Updates in the management of connective tissue disease-associated interstitial lung disease |
| title_short | Updates in the management of connective tissue disease-associated interstitial lung disease |
| title_sort | updates in the management of connective tissue disease associated interstitial lung disease |
| topic | antifibrotic biologicals connective tissue disease–interstitial lung disease treatment |
| url | http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2021;volume=16;issue=5;spage=109;epage=115;aulast=Kavadichanda |
| work_keys_str_mv | AT chengappakavadichanda updatesinthemanagementofconnectivetissuediseaseassociatedinterstitiallungdisease AT gsrsnknaidu updatesinthemanagementofconnectivetissuediseaseassociatedinterstitiallungdisease |